PANION & BF BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 94.7 TWD | +0.74% |
|
-1.97% | -15.45% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 6,408 | 6,584 | 6,530 | 6,448 | 15,347 | 9,603 |
| Enterprise Value (EV) 1 | 5,741 | 6,230 | 7,395 | 6,613 | 15,382 | 9,827 |
| P/E ratio | 40.1 x | 40.9 x | 236 x | 57 x | 84.4 x | 124 x |
| Yield | 2.16% | 2.1% | 0.82% | 1.99% | 1.12% | 1.34% |
| Capitalization / Revenue | 4.55 x | 4.18 x | 4.16 x | 3.39 x | 6.4 x | 5.1 x |
| EV / Revenue | 4.08 x | 3.96 x | 4.71 x | 3.48 x | 6.41 x | 5.22 x |
| EV / EBITDA | 22.6 x | 23 x | 46.2 x | 24 x | 28.2 x | 33 x |
| EV / FCF | 65.6 x | -145 x | -40.3 x | 35.2 x | 51.2 x | 210 x |
| FCF Yield | 1.53% | -0.69% | -2.48% | 2.84% | 1.95% | 0.48% |
| Price to Book | 4.74 x | 4.84 x | 5.27 x | 3.34 x | 7.65 x | 5.02 x |
| Nbr of stocks (in thousands) | 76,739 | 76,739 | 76,739 | 85,739 | 85,739 | 85,739 |
| Reference price 2 | 83.50 | 85.80 | 85.10 | 75.20 | 179.0 | 112.0 |
| Announcement Date | 3/18/19 | 3/26/20 | 3/22/21 | 3/25/22 | 3/31/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,409 | 1,574 | 1,569 | 1,901 | 2,399 | 1,882 |
| EBITDA 1 | 253.7 | 270.3 | 160.2 | 275.7 | 546.3 | 298.2 |
| EBIT 1 | 212.5 | 223.9 | 104.5 | 165.3 | 414 | 156.8 |
| Operating Margin | 15.09% | 14.23% | 6.66% | 8.7% | 17.26% | 8.33% |
| Earnings before Tax (EBT) 1 | 244.4 | 226.3 | 89.41 | 182.7 | 333.4 | 168.7 |
| Net income 1 | 159.2 | 161.3 | 27.9 | 104.4 | 182.3 | 77.22 |
| Net margin | 11.3% | 10.25% | 1.78% | 5.49% | 7.6% | 4.1% |
| EPS 2 | 2.080 | 2.100 | 0.3600 | 1.319 | 2.120 | 0.9000 |
| Free Cash Flow 1 | 87.58 | -43.02 | -183.4 | 187.8 | 300.7 | 46.79 |
| FCF margin | 6.22% | -2.73% | -11.69% | 9.88% | 12.54% | 2.49% |
| FCF Conversion (EBITDA) | 34.52% | - | - | 68.11% | 55.04% | 15.69% |
| FCF Conversion (Net income) | 55.02% | - | - | 179.88% | 164.89% | 60.6% |
| Dividend per Share 2 | 1.800 | 1.800 | 0.7000 | 1.500 | 2.000 | 1.500 |
| Announcement Date | 3/18/19 | 3/26/20 | 3/22/21 | 3/25/22 | 3/31/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2023 Q1 | 2023 Q2 | 2023 Q3 |
|---|---|---|---|---|
| Net sales 1 | 529.4 | - | 470.1 | 474.6 |
| EBITDA | - | - | - | - |
| EBIT 1 | 67.13 | - | 45.38 | 42.68 |
| Operating Margin | 12.68% | - | 9.65% | 8.99% |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | - | 22.69 | - | - |
| Net margin | - | - | - | - |
| EPS | - | 0.2600 | - | - |
| Dividend per Share | - | - | - | - |
| Announcement Date | 11/11/21 | 5/15/23 | 8/11/23 | 11/14/23 |
1TWD in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | 864 | 165 | 34.7 | 225 |
| Net Cash position 1 | 666 | 354 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | 5.394 x | 0.5997 x | 0.0635 x | 0.7529 x |
| Free Cash Flow 1 | 87.6 | -43 | -183 | 188 | 301 | 46.8 |
| ROE (net income / shareholders' equity) | 14.6% | 11.9% | 2.15% | 6.58% | 9.26% | 3.94% |
| ROA (Net income/ Total Assets) | 8.62% | 7.47% | 2.62% | 3.43% | 8.56% | 3.1% |
| Assets 1 | 1,847 | 2,160 | 1,065 | 3,045 | 2,131 | 2,493 |
| Book Value Per Share 2 | 17.60 | 17.70 | 16.20 | 22.50 | 23.40 | 22.30 |
| Cash Flow per Share 2 | 7.760 | 4.750 | 4.040 | 3.260 | 5.410 | 6.240 |
| Capex 1 | 39.8 | 112 | 101 | 170 | 199 | 181 |
| Capex / Sales | 2.83% | 7.1% | 6.45% | 8.94% | 8.28% | 9.63% |
| Announcement Date | 3/18/19 | 3/26/20 | 3/22/21 | 3/25/22 | 3/31/23 | 3/14/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.45% | 250M | |
| +29.98% | 682B | |
| +31.77% | 586B | |
| -3.52% | 364B | |
| +18.59% | 327B | |
| +4.07% | 285B | |
| +16.51% | 240B | |
| +9.40% | 209B | |
| -8.79% | 203B | |
| +7.09% | 165B |
- Stock Market
- Equities
- 1760 Stock
- Financials Panion & Bf Biotech Inc.